Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Comparative drug screening in NUT midline carcinoma

The NUT midline carcinoma (NMC) is a rare but fatal cancer for which systematic testing of therapy options has never been performed.

Research

Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis

Hematopoiesis occurs in a complex bone marrow microenvironment in which bone marrow stromal cells provide critical support to the process through direct cell...

Research

Basal cell carcinomas on sun-protected vs. sun-exposed body sites: A comparison of phenotypic and environmental risk factors

There are indications that risk factors for BCC may differ according to the anatomic site of the tumour but this is not well understood.

Research

Birthweight and childhood cancer: Preliminary findings from the international childhood cancer cohort consortium (I4C)

Background Evidence relating childhood cancer to high birthweight is derived primarily from registry and case-control studies.

Research

Lessons from 50 years of curing childhood leukaemia

One of the great success stories of modern medicine is undoubtedly the remarkable improvement in outcome for childhood cancer, achieved through the work of...

News & Events

The goal of Project Childrens' Cancer is to discover new, less toxic therapies

The goal of Project Children's Cancer is to discover new therapies that are more effective and less toxic to fight aggressive cancers in babies and children.

News & Events

More research needed into mums smoking and childhood brain tumours

Researchers from Perth's Telethon Institute are calling for further investigation into a potential link between maternal smoking and childhood brain tumours.

Research

A New Era for PPARγ: Covalent Ligands and Therapeutic Applications

Peroxisome proliferator-activated receptor γ (PPARγ) is a prominent ligand-inducible transcription factor involved in adipocyte differentiation, glucose homeostasis, insulin sensitivity, inflammation, and cell proliferation, making it a therapeutic target for diabetes, metabolic syndrome, autoimmune diseases, and cancer. 

Research

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial

Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial.

Research

“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials

Each year, approximately 1000 children in Australia and New Zealand, aged 0–14 years, are diagnosed with cancer. Despite paediatric cancer accounting for less than 1% of all cancer cases, the impact on their families and communities is profound and disproportionate.